ArticleBMC psychiatry2025
Changes in olfactory function and serum interleukin-6 levels in the acute phase of bipolar I disorder: a longitudinal study.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of immune cell phenotypes and metabolites in bipolar disorder risk: a Mendelian randomization-based mediation analysis.European archives of psychiatry and clinical neuroscience · 2026Article
- Shifting the paradigm in bipolar disorder: moving beyond conventional inflammatory markers to novel EBI3-containing heterodimeric cytokines.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesIn this study, we horizontally compared olfactory function and interleukin-6 levels in bipolar disorder (BD) patients with manic and depressive episodes with those in healthy controls. We also compared these variables longitudinally between patients in the acute versus euthymic phase, and assessed the correlation between olfactory function and interleukin-6 in BD patients overall. The purpose of this study was to search potential biomarkers for early diagnosis and efficacy evaluation of BD, and to provide more clinical evidence for exploring the hypothesis of neuroimmune pathways in BD.
methodsThe study included 50 manic BD patients, 31 depressive BD patients, and 59 healthy controls, and all patients were followed until they entered the euthymic phase. Olfactory sensitivity (OS) and olfactory identification (OI) were evaluated via the Sniffin' Sticks test. We collected blood samples and measured serum interleukin-6 levels.
resultsThe results showed that the OS and OI in manic BD group and depressive BD group were significantly lower than those in healthy controls (P < 0.05, Cohen's d = 0.657, 0.446, η
conclusionThe dynamic recovery of OS (impaired in acute phase, restored in euthymia) suggests its potential as a disease-activity biomarker in BD, while persistent OI deficits may reflect trait-related neurobiological features. However, their specificity and clinical utility require rigorous validation. There is a potential correlation between inflammatory activity and olfactory dysfunction in manic BD patients, but its causal relationship and specific mechanism need to be further verified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.